This study is testing a new way to perform stem cell transplants for children and young adults with serious blood disorders. It uses a special process called the CliniMACS TCR α/β Reagent Kit and CliniMACS CD19 to prepare stem cells from a donor before they are given to the patient. This method aims to make the transplant safer and more effective, especially when a perfectly matched donor isn't available. The study is looking for participants between 1 month and 60 years old who have life-threatening blood cancers or other blood disorders and are eligible for a stem cell transplant. The main goal is to see how many participants develop a condition called acute GvHD (graft-versus-host disease) within 100 days after the transplant. The current status of this study is unclear.

Study design

This is a single-center, open-label, single-arm clinical trial aiming to enroll 204 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint measures acute GvHD through Day 100 after the stem cell transplant.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.